IDYA supply chain intelligence for IDEAYA Biosciences, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AZN | AstraZeneca PLC | 92% | AstraZeneca will supply Imfinzi ® . |
| AZN | AstraZeneca PLC | 92% | Reciprocal relationship from AZN graph: Reciprocal relationship from IDYA graph: AstraZeneca will supply Imfinzi ® . |
| JEFFERIES-LLC | JEFFERIES-LLC | 92% | under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having aggregate gross proceeds of … |
| BIOCYTOGEN-PHARMACEUTICALS-CO-LTD | BIOCYTOGEN-PHARMACEUTICALS-CO-LTD | 90% | timing and amount of any milestone, royalty or other payments due under any current or future collaboration or license agreement, including the Option and License Agreement with Biocytogen Pharmaceut… |
| NVS | Novartis AG | 90% | Reciprocal relationship from NVS graph: Reciprocal relationship from IDYA graph: Reciprocal relationship from NVS graph: Reciprocal relationship from IDYA graph: timing and amount of any milestone, r… |
| NVS | Novartis AG | 90% | timing and amount of any milestone, royalty or other payments due under any current or future collaboration or license agreement, including the License Agreement with Novartis |
| UNIVERSITY-OF-MANCHESTER | UNIVERSITY-OF-MANCHESTER | 90% | timing and amount of any milestone, royalty or other payments due under any current or future collaboration or license agreement, including the Option and License Agreement with CRT and University of… |
| HENGRUI-PHARMA | HENGRUI-PHARMA | 85% | IDE849/SHR-4849 (licensed from Hengrui Pharma) |
| GILD | Gilead Sciences, Inc. | 72% | sertib (PKC) Phase 2/3 clinical trials, IDE397 (MAT2A) Phase 1/2 clinical trials, IDE849 (DLL3) Phase 1 clinical trial, IDE161 (PARG) Phase 1/2 clinical trial, IDE275 (Werner Helicase) Phase 1 clinic… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from IDYA graph: sertib (PKC) Phase 2/3 clinical trials, IDE397 (MAT2A) Phase 1/2 clinical trials, IDE849 (DLL3) Phase 1 clinical tria… |
| MANU | Manchester | 72% | Reciprocal relationship from MANU graph: Reciprocal relationship from IDYA graph: mbined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit… |
| MANU | Manchester | 72% | mbined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit and working capital. Our operating results may fluctuate significantly, which wil… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| SERVIER | SERVIER | 90% | The Company has financed its operations primarily through the sale and issuance of common stock, the upfront payment and certain milestone payments received from GSK (as defined below) and the upfron… |
| MANU | Manchester | 72% | mbined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit and working capital. Our operating results may fluctuate significantly, which wil… |
| MANU | Manchester | 72% | Reciprocal relationship from MANU graph: Reciprocal relationship from IDYA graph: mbined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit… |
| BIOCYTOGEN-PHARMACEUTICALS-CO-LTD | BIOCYTOGEN-PHARMACEUTICALS-CO-LTD | 62% | eriods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit and working capital. Our operating results may fluctu… |
| FOR-IDE397-SERVIER-PHARMACEUTICALS-LLC | FOR-IDE397-SERVIER-PHARMACEUTICALS-LLC | 62% | uthority disagreeing as to the design or implementation of our clinical trials; • delays in obtaining regulatory authorization to commence a clinical trial; • reaching agreement on acceptable terms w… |
| JIANGSU-HENGRUI-PHARMACEUTICALS-CO-LTD | JIANGSU-HENGRUI-PHARMACEUTICALS-CO-LTD | 62% | eriods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit and working capital. Our operating results may fluctu… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IDYA-DEBT-10191 | Warrants outstanding: 285715 | 90% | xbrl warrant detail from xbrl 2024-12-31. |
| IDYA-DEBT | Debt stack $28.6M | 90% | Market cache reports total debt of $28.6M. |
| IDYA-DEBT-10192 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2019-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| IDYA-OWNER-JANUS-HENDERSON-GROUP-PLC | JANUS HENDERSON GROUP PLC | 90% | 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 260 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| DGNX | Diginex Limited | 100.00 | 2 | |
| CBAN | Colony Bankcorp, Inc. | 100.00 | 2 | |
| ALCY | Alchemy Investments Acquisition Corp 1 | 100.00 | 2 | |
| CPMV | Mosaic ImmunoEngineering, Inc. | 100.00 | 2 | |
| AAUAF | Almaden Minerals Ltd. | 100.00 | 2 | |
| AUGO | Aura Minerals Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| BCAX | Bicara Therapeutics Inc. | 100.00 | 2 | |
| BANL | CBL International Limited | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 2 | |
| ALGM | Allegro MicroSystems, Inc. | 100.00 | 2 | |
| RYAOF | Ryanair Holdings plc | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| DOYU | DouYu International Holdings Limited | 100.00 | 2 |